We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$97.5M
AUM Growth
+$12.7M
Cap. Flow
-$2.23M
Cap. Flow %
-2.29%
Top 10 Hldgs %
80.62%
Holding
30
New
10
Increased
6
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
QLTI
QLT Inc
QLTI
+$5.81M
2
ALR
Alere Inc
ALR
+$3.25M
3
PCRX icon
Pacira BioSciences
PCRX
+$2.56M
4
VCEL icon
Vericel Corp
VCEL
+$2.4M
5
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$2.34M

Top Sells

Rank Stock Value
1
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$12.7M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$12.2M
3
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$3.38M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$1.99M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$1.9M

Sector Composition

Rank Sector Weight
1 Healthcare 62.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTP
26
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-20,000
Closed -$92K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Stonepine Capital Management held 30 positions worth $97.5M, up 15% from $84.8M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Stonepine Capital Management's Q2 2016 filing shows 10 new, 6 increased, 5 reduced and 7 closed positions. Its largest new stake was QLT Inc: 3,779,274 shares worth $5.37M. The largest sale was Sciclone Pharmaceuticals Inc, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 92% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2016 buy was QLT Inc: 3,779,274 shares worth $5.37M.
  • Stonepine Capital Management added most to Vericel Corp in Q2 2016, an estimated $2.4M increase.
  • Stonepine Capital Management's biggest Q2 2016 reduction was Sciclone Pharmaceuticals Inc, cutting an estimated $12.7M.
  • Stonepine Capital Management fully exited Pernix Therapeutics Holdings, Inc. in Q2 2016, selling an estimated $3.38M.
  • Stonepine Capital Management's ten largest holdings make up 81% of its $97.5M portfolio in Q2 2016.
  • Stonepine Capital Management opened 10 new positions and closed 7 in Q2 2016.
  • Stonepine Capital Management's portfolio value rose 15% quarter-over-quarter to $97.5M.

Based on Stonepine Capital Management's 13F filing for Q2 2016, filed 10 Aug 2016.